Join Our Team

We believe in doing good and thorough science, through which we aim to deliver safe and efficacious biosimilars for treating debilitating diseases.

Our endeavour is to create a meaningful difference in people’s health and lives. Our employees are integral to this vision, and we believe that everyone who comes on-board will be provided with an opportunity to express and excel in their careers.

We are always on the lookout for passionate, driven, and experienced individuals who are willing to partner with us on this exciting journey towards “Curing people and Healing lives”.

Our Values

Business Care

Operational Excellence

Stakeholder Orientation

Quality and Innovation

People Care

Fairness, Humility and Respect

Teamwork and Synergy

Applied Learning

Organisational Care

Accountability

Integrity

Achievement

0 Openings

Sorry, there's no results for ""

Latest News

CuraTeQ Biologics successfully completes Phase I study for Denosumab biosimilar
Press Release

10 April 25

CuraTeQ Biologics successfully completes Phase I study for Denosumab biosimilar

Read More
CuraTeQ Biologics receives CHMP positive opinion for Pegfilgrastim biosimilar
Press Release

31 January 25

CuraTeQ Biologics receives CHMP positive opinion for Pegfilgrastim biosimilar

Read More
CuraTeQ Biologics receives UK MHRA approval for Bevqolva™ (Bevacizumab biosimilar)
Press Release

21 December 24

CuraTeQ Biologics receives UK MHRA approval for Bevqolva™ (Bevacizumab biosimilar)

Read More
CuraTeQ Biologics receives CHMP positive opinion for Filgrastim biosimilar
Press Release

13 December 24

CuraTeQ Biologics receives CHMP positive opinion for Filgrastim biosimilar

Read More
EMA grants GMP certificate to CuraTeQ Biologics’ manufacturing facility in Hyderabad
Press Release

12 November 24

EMA grants GMP certificate to CuraTeQ Biologics’ manufacturing facility in Hyderabad

Read More
CuraTeQ Biologics successfully completes Phase 1 trial for Omalizumab biosimilar
Press Release

15 March 24

CuraTeQ Biologics successfully completes Phase 1 trial for Omalizumab biosimilar

Read More
Auro Peptides completes US FDA inspection with zero observations
Press Release

17 February 24

Auro Peptides completes US FDA inspection with zero observations

Read More
CuraTeQ Biologics’ Trastuzumab Biosimilar receives recommendation for marketing authorization in India
Press Release

17 January 24

CuraTeQ Biologics’ Trastuzumab Biosimilar receives recommendation for marketing authorization in India

Read More
CuraTeQ Biologics eyes ‘WuXi’ moment to kickstart Indian bio-CDMO sector
Press Release

20 November 23

CuraTeQ Biologics eyes ‘WuXi’ moment to kickstart Indian bio-CDMO sector

Read More
Overview
CuraTeQ Biologics

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

You can adjust your preferences below.

Essential Cookies

Essential Cookies should be enabled at all times so that we can save your preferences for cookie settings. If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

Google Analytics

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages. Keeping this cookie enabled helps us to improve our website.